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Previous colostrum trials have been conducted with serum IgA levels and upper 
respiratory tract infections and reports document beneficial immunomodulatory effects 
after colostrum supplementation and no adverse effects. Having previously demonstrated 
that colostrum supplementation in athletes increased S-IgA levels, it was hypothesized 
that colostrum and egg yolk supplementation would decrease upper respiratory tract 
infections (URTIs). Twenty-five female subjects and 24 male subjects volunteered for the 
study and were randomly assigned into a placebo and a Transfer Factor group 
(n = 22 placebo, n = 26 Transfer Factor) to take two capsules every day for 6 weeks. 
After 6 weeks, there was no difference between the placebo and Transfer Factor groups 
in S-IgA levels, days sick, severity of illness, and severity of symptoms. In conclusion, 
during a 6-week supplementation protocol with 600 mg/d (420 mg of colostrum, 180 mg 
of egg yolk) of Tri-Factor Transfer Factor, there was no increased salivary IgA and 
reduced frequency and duration of cold and flu symptoms compared to placebo in a 
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Influenza spreads around the world in seasonal epidemics, resulting in loss of 
productivity in the work force, loss of income by the patient, and the intangible cost of 
pain, grief, and social disruption every year. In the United States, influenza is responsible 
for a total cost of over $10 billion per year, while it has been estimated that a future 
pandemic could cause hundreds of billions of dollars in direct and indirect costs (1). 
Influenza, commonly referred to as the flu, is an infectious disease caused by 
Ribonucleic acid (RNA) viruses. RNA viruses generally have very high mutation rates 
compared to Deoxyribonucleic acid (DNA) viruses so it is difficult to make effective 
vaccines to prevent diseases caused by RNA viruses. The most common symptoms of the 
disease are chills, fever, sore throat, muscle pains, severe headache, coughing, 
weakness/fatigue, and general discomfort. 
An upper respiratory tract infection (URTI) involves the upper respiratory tract 
(nose, sinuses, pharynx, or larynx) and can be caused by bacterial and/or viral infections. 
Viral URTIs are more common than bacterial URTIs. In the United States, viral URTIs 
are the most common infectious illness in the general population and are the leading 
reasons for people missing work and school (2). 
  
2 
The mucosal immune system represents the first line of immunological defense 
against pathogens encountering the mucosal surfaces of the body, like those lining the 
upper respiratory tract. Immunoglobulin A (IgA) is the primary immunoglobulin isotype 
induced at the mucosal surface. Mucosal secretory IgA provides protection against 
bacterial and viral pathogens and neutralizes microbial toxins (3, 4). IgA is the principle 
mucosal antibody class and is synthesized locally by white blood cells. 
Although the flu vaccine is the best flu prevention method, antiviral flu 
medication is also available by prescription for products such as Tamiflu® (oseltamivir), 
Flumadine® (rimantadine), Symmetrel® (amantadine), and Relenza® (zanamivir). In 
addition, many dietary supplements such as Vitamin C and various Zinc containing 
products have been developed and marketed for the prevention and treatment of cold and 
flu. Bovine colostrum has been proposed as another dietary supplement that may help in 
the prevention and treatment of cold and flu. 
Bovine colostrum is cow milk secreted during the first few days after calving. Its 
importance for the development and maintenance of immune health in calves has been 
known for decades (5). Bovine colostrum is an extremely rich source of 
immunoglobulins. The concentration of immunoglobulin G (IgG) and immunoglobulin A 
(IgA) in bovine colostrum is 100-fold higher than in normal milk (6). Along with IgA 
secreted in the breast milk, residual IgG absorbed through the placenta provides the 
human fetus with humoral immunity before its own immune system develops. IgG can 
bind to many kinds of pathogens, for example viruses, bacteria, and fungi, and protects 
the body against them. Immunoglobulin Y (IgY) is the major immunoglobulin in birds. It 
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is also found together with IgA in chicken egg yolk. Avian IgY is the functional 
equivalent to mammalian IgG. 
Recently, egg yolk-derived IgY has been combined with bovine 
colostrum-derived IgA to produce a dietary supplement called Tri-Factor Transfer Factor. 
The supplement has been marketed as a tool for boosting immune competence and 
reducing the incidence, duration, and/or severity of colds and flu. The goal of this study 
was to determine the efficacy of Transfer Factor in this regard. The rationale for 
examining the potential immunological benefits of Tri-Factor Transfer Factor are 
four-fold. First, there is a strong correlation between circulating or salivary IgA levels 
and URTI (7-9). Second, there is a strong clinical utility for using salivary IgA levels as a 
biomarker of immune competence (10-16). Third, carbohydrate and glutamine 
supplementation may act as an energy source or as building blocks of immunoglobulins 
but do not contain whole immunoglobulins in their formulation (17-25). Fourth, 20 g/day 
of a Dynamic Colostrum supplement containing 74 µg IGF-I, 4.5 g IgG, and 0.3 g IgA 
(total energy 340 kJ: 6 g protein, 14 g carbohydrates) yielded a 33% greater increase in 
salivary IgA levels than placebo (26-29). 
We hypothesized that during a 6-week supplementation protocol with 600 mg/d 
(420 mg of colostrum, 180 mg of egg yolk) of Tri-Factor Transfer Factor, there would be 
an increased salivary IgA and reduced frequency and duration of cold and flu symptoms 






The inclusion criteria were healthy men and women aged 18-40 years. The 
exclusion criteria included the following: currently smoking, cardiovascular disease, 
cancer, diabetes, liver disease, renal insufficiency, any chronic disease that might 
interfere with study participation, BMI above 40 kg/m2, consumption of > 12 alcoholic 
drinks weekly, unwillingness to stop current supplement intake, and any allergic response 
to eggs (the supplement is egg-based). Any volunteer who did not know whether he or 
she had an egg or milk allergy were excluded. Women who were pregnant or lactating 
were also excluded from the study. 
Participants were volunteers from students enrolled in a Nutrition 1020 class 
recruited by word of mouth and flyers posted at The University of Utah. Interested 
volunteers filled out a medical history questionnaire. If they met inclusion/exclusion 
criteria, then they were scheduled for a meeting to review the consent form with study 
staff so that they could decide if they wished to participate. Twenty-five female subjects 
and 24 male subjects volunteered for the study and were randomly assigned into a 
placebo and a Transfer Factor group. In the placebo group, there were 12 female and 
11 male participants and in the Transfer Factor group, there were 13 female and 13 male 
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participants. Written informed consent was obtained from each participant prior to 
research. Each participant filled out a medical history questionnaire (Appendix) prior to 
enrollment. 
Experimental Design 
A randomized, placebo controlled, double blind, trial was used to test the efficacy 
of Tri-Factor Transfer Factor formula to reduce the frequency and or duration of upper 
respiratory tract infection and increase salivary IgA levels compared to placebo. 
Participants were randomly assigned to either a placebo group or supplement group for a 
period of 8 weeks consisting of a 1-2 week baseline period to establish a baseline salivary 
IgA secretion rate followed by a 6-week supplement or placebo period. They received the 
pills and were instructed to take two capsules daily. Table 1 shows the composition of 
Transfer Factor supplement and placebo capsules. Participants were instructed to 
maintain their normal exercise and dietary habits for the duration of the study. Diet 
records were also collected at week 3 and 6. These records were analyzed to confirm that 
participants kept a consistent diet, and that any changes in parameters measured were due 
to the intervention rather than changes in diet. 
Each week, saliva samples were also collected to measure salivary IgA 
production. Salivary IgA were used as a marker of immune function/competence. 
Salivary IgA secretion rates have been extensively used in previous studies as a marker of 
immune function in humans (9, 30). 
Each week, subjects also filled out a report (Appendix) logging the days they 




Composition of Transfer Factor Supplement 
Ingredient  Amount per 2 capsules (mg)  
Bovine colostrum filtrate  420 
Egg yolk concentrate  180 
Maltodextrin (tableting agent)  170 
 
electronically or on paper based on the subject’s personal preference. The report used a 
scale of severity to rank degree of illness ranging from zero to five with the following 
definitions: 0; feeling fine, not sick, no symptoms, 1; little if any interference with daily 
activities, 2; feeling sick, but can get through the day, 3; can do a little but must rest a lot, 
4; confined to bed, 5; hospitalized. 
Data were collected and analyzed for number of days sick per week, severity of 
their illness on days sick, and number of days sick in entire experimental period. 
Dietary Records 
Subjects were instructed on how to keep 3-day diet records during the third and 




Health History Survey 
A detailed history with an emphasis on respiratory history were collected 
(Appendix) prior to enrollment in the study. 
Saliva Sampling for IgA Measurement 
Each week, the subjects were required to submit a saliva sample according to the 
following procedure: 
1. Subjects must not have had any dental work or consumed alcohol 24 hrs prior to 
collection. 
2. Subjects must not have eaten any food or beverage, other than water, for 45 min 
prior to collection. 
3. Subjects must rinse their mouth 10 min before collection. 
4. Subjects filled out a questionnaire regarding their current health, 
medication/supplement use, compliance to the above and other pertinent details. 
5. Subjects chewed a 5 cm square of ParaFilm and allow their passive drool to 
collect in a graduated tube for 5 min. 
6. Samples were immediately placed on ice and then frozen (-70°C) within 4 hrs. 
Salivary IgA Assay 
Saliva samples were analyzed through the use of commercial ELISA assay kits 
following the manufacturer’s instructions. Salivary IgA levels were measured using a 
BioRad X-Mark plate reader at 450 nm detection and 490-630 nm correction, as 
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described in the Salimetrics assay kit instructions. Reagents were reconstituted 10 min 
before assay. Plate layout was set up. Five final concentrations of standards (600 µl/ml, 
200 µl/ml, 66.7 µl/ml, 22.2 µl/ml, 7.4 µl/ml, and 2.5 µl/ml) were made. One hundred µl 
of 1 X S-IgA diluents were added to each tube. Twenty-five µl of saliva were added to 
the appropriate tube. A separate tube for standard, control, and zero value were also 
made. Fifty µl of diluted antibody-enzyme conjugate were mixed gently in each tube. 
Then, 50 µl of solutions were added to each well according to plate layout. Fifty µl of 
1 X S-IgA diluents were added to the NSB wells. The sealed plate was incubated at room 
temperature for 90 min with continual mixing at 400 rpm. Next, the plate was washed 
6 times with 1 X wash buffer. Fifty µl of TMB solution were added to each well and were 
mixed on plate rotator for 5 min at 500 rpm. Then the plate was incubated in the dark at 
room temperature for 40 min. Fifty µl stop solution was added to each well and was 
mixed on plate rotator for 3 min at 500 rpm until all wells turned yellow. Plates were read 
in micro plate reader at 450 nm within 10 min of adding stop solution. The average OD 
was calculated for all wells. The average OD for the NSB wells was subtracted from the 
average OD of the other wells. The percent bound (B/Bo) for each standard, control, and 
unknown was calculated by dividing the average OD for the zero (Bo). Concentration of 
controls and unknowns were determined by fitting to a 4-parameter sigmoid minus curve. 
Concentrations were multiplied by 5 to obtain final S-IgA in µl/ml. 
Statistical Analyses 
A Chi square test (SPSS v.19.0.0) was used to detect significant differences 
between Transfer Factor and placebo groups regarding the following parameters: total 
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days with cold and flu-like symptoms, duration of symptoms with each illness reported. 
A repeated-measures ANOVA was used to analyze weekly salivary IgA secretion 
between Transfer Factor and placebo groups. Significance was accepted at p < 0.05. One 
male participant from placebo group left the study after 3 weeks because he did not like 
to continue taking the pills. Data from 48 were used for analysis. Any participants with 
one or more missing saliva samples were excluded from S-IgA data analysis. Three 
subjects from the Transfer Factor group did not show up for at least one of the saliva 
collection sessions. Therefore, the data analysis for S-IgA included 22 participants in the 
placebo group and 19 participants in the Transfer Factor group. Variability is expressed 
as Standard Deviation throughout unless otherwise indicated. Wherever the data were not 







The placebo and Transfer Factor group had similar demographic characteristics in 
average height, weight, and BMI (p ≥ 0.496, Table 2). However the placebo group was 
slightly older on average than the Transfer Factor group (23.0 ± 4.2 vs. 21.5 ± 2.0, 
p = 0.020). There were no differences in the percentage of females or in the percentage of 
those inoculated with either the flu or H1N1 vaccine (p ≥ 0.307). In addition, there were 
no significant differences in energy intake, carbohydrate intake, protein intake, fat intake, 
and micronutrients intake at weeks 3 and 6 between the placebo and Transfer Factor 
groups (p ≥ 0.569). 
S-IgA 
Overall, the linear, quadratic, cubic, quartic, and fifth order polynomial treatment 
group by time interactions were all nonsignificant (p ≥ 0.330, Figure 1). By contrast, 
there was a significant sixth order polynomial treatment group by time interaction 








(n = 22) 
Transfer Factor 
(n = 26) P Value 
Height (cm) 173.47 ± 8.91 171.45 ± 11.48 0.496 
Weight (kg) 66.41 ± 9.86 66.69 ± 13.58 0.937 
BMI (kg/m2) 22.05 ± 2.68 22.67 ± 3.97 0.526 
Gender Female n = 12 (54.5%) 
Female 
n = 13 (50.0%) 0.981 
Age (yrs) 23 20.5 0.02 
Flu Shot 
(% inoculated) n = 7 (31.8%) n = 4 (15.4%) 0.315 
H1N1 
(% inoculated) n = 6 (27.3%) n = 3 (11.5%) 0.307 
 
 
Figure 1: The average in S-IgA secretion between 
experimental groups (6th order polynomial treatment 
group X time interaction, p = 0.005; all other treatment 
group X time interactions, p ≥ 0.330). 
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interactions were nonsignificant, there were no meaningful differences in the magnitude 
of the S-IgA changes over time between the placebo and the Transfer Factor groups. 
Days Sick 
Average total days sick per week are shown in Figure 2. There was no significant 
differences in average number of total days sick per week between the placebo and 
Transfer Factor group (p = 0.411, Table 3). 
Severity of Illness 
The average severity of illness between experimental groups is shown in Figure 3. 
There was no significant difference in severity of illness between the placebo group and 
the Transfer Factor group (p = 0.407, Table 4). 
 
Figure 2: The average number of total days sick per 




Average Number of Total Days Sick from 
Week 2 to 7 between Experimental Groups 
(p = 0.411) 
Placebo Transfer Factor 
4.68 ± 5.13 7.27 ± 8.26 
 
 
Figure 3: The average weekly severity of illness between 
experimental groups. 
Table 4 
Average Severity of Illness from Week 2 to 
7 between Experimental Groups 
(p = 0.407) 
Placebo Transfer Factor 




Severity of Symptoms 
Figure 4 describes the severity of symptoms for each experimental group. This 
figure shows the average severity range from a low of 1.0 ± 0.0 in week 6 and a high of 
1.72 ± 0.9 in week 3 in the placebo group and a low of 1.0 ± 0.0 in week 7 and 1.47 ± 0.8 
in week 3 in the Transfer Factor group. There was no difference in severity of symptoms 
between the experimental groups (p = 0.407, Table 5). 
 
Figure 4: The average weekly severity of symptoms between 
experimental groups. 
Table 5 
Average Severity of Symptoms from Week 2 
to 7 between Experimental Groups 
(p = 0.407) 
Placebo Transfer Factor 





Findings of this trial suggest that there was no difference between the placebo and 
Transfer Factor groups in S-IgA levels (Figure 1), days sick (Figure 2), severity of illness 
(Figure 3), and severity of symptoms (Figure 4). Although there was no difference in 
S-IgA secretion between the placebo and Transfer Factor groups, there was a significant 
sixth order polynomial treatment group by time interaction (Figure 1). However, 5 out of 
6 of the polynomial treatment group by time interactions were nonsignificant. Moreover, 
there were no clinically meaningful differences in the magnitude of the S-IgA changes 
over time between the placebo and the Transfer Factor groups. There was no difference 
in the average number of total days sick from week 2 to 7 between the placebo and 
Transfer Factor groups (Table 3). There was no difference in average severity of illness 
from week 2 to 7 between the placebo and the Transfer Factor groups (Table 4). Finally, 
there was no difference in the average severity of symptoms from week 2 to 7 between 
the placebo and the Transfer Factor groups (Table 5). 
The efficacy of colostrum but not Transfer Factor itself has been previously 
reported in modulation of IgA levels and upper respiratory tract infections in non-English 
language journals. These reports document beneficial immunomodulatory effects after 
Transfer Factor supplementation and no adverse effects. Because these studies have not 
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been published in peer reviewed English language journals, the results are not easily 
accessible to English speaking health care practitioners. However, Transfer Factor has yet 
to be evaluated in a healthy population with the intent of determining if this supplement 
can reduce the frequency or the duration of colds and flu. Transfer Factor is comprised of 
colostrum (bovine milk secretion during the early days of lactation) and chicken egg 
yolk. 
Several colostrum but not Transfer Factor supplementation trials have been 
conducted with serum IgA levels and upper respiratory tract infections as study outcomes 
(26-29). Almost all of these trials were conducted in athletic samples. For example, 
2 weeks of 20 g/d colostrum supplementation increased S-IgA levels by 33%, on average, 
in a sample of 30 adult athletes (27). Another study suggests five weeks supplementation 
of 10 g/d bovine colostrum increases S-IgA concentration in athletes during training (29). 
In addition, in two studies, fewer athletes reported Upper Respiratory Syndrome (URS) 
when consuming 20 g/d bovine colostrum for 2 weeks (27, 28). Though the 
aforementioned studies have all reported positive changes in salivary IgA, our study 
found that the colostrum cocktail found in Transfer Factor did not affect salivary IgA 
concentrations or production rate. Possible explanations for the above benefits of 
colostrum supplementation as compared to the present null findings of Transfer Factor 
supplementation include the different supplement compositions, different supplement 
dosages, different demographic characteristics of the participants, and different durations 
of follow-up. In the colostrum supplementation studies above, colostrum is the only 
active ingredient, and the study durations were longer than the present Transfer Factor 
trial. In addition, the colostrum supplementation studies were primarily conducted in 
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athletic men who were slightly older than the participants in the present trial. We also 
used a twice daily supplement of both colostrum (210 mg) and egg yolk (90 mg), and we 
followed our participants for only 7 weeks. 
Our trial has some notable strengths and weaknesses. For instance, our trial used a 
double blind placebo-controlled randomized experimental design. In addition, we 
assessed S-IgA secretion. However, the sample size of each experimental group was 
small (n = 22 placebo, n = 26 Transfer Factor). Moreover, our sample size estimate was 
based only on the ability to detect the difference in S-IgA levels based on the above 
colostrum supplementation trials. By contrast, our trial was not adequately powered to 
detect experimental group differences in illness, severity of illness, and severity of 
symptoms. Finally, S-IgA was our only marker of immune competency, and we only 
followed the participants for 7 weeks. 
Given the limitations discussed, suggested modifications for future studies would 
address sample size, duration of study, and number of immune markers measured. For 
example, bigger sample size (at least 50 subjects per experimental group), longer duration 
of follow up (a whole winter season), and more than one marker of immune competence 
(IgG) are recommended for future studies. The other possibility is the dosage of the 
supplements. In this study, all subjects in the Transfer Factor group took 420 mg of 
colostrum and 180 mg of egg yolk every day. Because the active ingredient of the 
supplements gets cleared out by the body and its clearance is under influence of fat free 
mass, maybe a metabolic clearance study has to be done to refine and individualize the 
dosage of the supplement based on the body weight. In addition, future studies should 
also exclude participants who have received flu and H1N1 vaccines. 
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We found no significant difference in S-IgA levels, number of days sick, severity 
of illness, and severity of symptoms in a sample of healthy young adults. We conclude 
that during a 6-week supplementation protocol with 600 mg/d (420 mg of colostrum, 
180 mg of egg yolk) of Tri-Factor Transfer Factor, there was no increased salivary IgA 
and reduced frequency and duration of cold and flu symptoms compared to placebo in a 






Medical History Questionnaire  
 
Personal Information 
Subject ID#_____________________ Date of Birth_________________________ 
Name__________________________ Address_________________________ 
Home phone____________________ Work phone______________________ 
Ht:____________ Wt:_________ BMI:____________ 
 
Health History 
Do you have a history any of the following conditions?  Please check all that apply and 
provide a brief explanation below: 
 
_____ pneumonia     _____ musculoskeletal problems 
_____ asthma (mild, mod., severe)   _____ cancer 
_____ recurrent bronchitis     _____ diabetes 
_____ allergies (airway) _____ hypertension 
_____ kidney problems/disease   _____ liver problems 
_____ thyroid abnormalities    _____ blood disorders 
_____ malabsorption disorders   _____ anemia  
_____ cardiac abnormalities/disease    _____ other, please explain below 
              
             
 
Flu shot Yes  No  H1N1 shot Yes  No 
Do you follow a special diet? (vegetarian, medical, etc.)      
Are you currently trying to lose or gain weight? (please specify if applicable) 
             
 
Please list any dietary supplements including vitamins, minerals, protein shakes, diet 
shakes, and herbs you currently take, or have taken in the last 2 weeks. 
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Please list any medications you are currently taking. 
             
             
             
 
Please list any known food or drug allergies. 
             
             




Transfer Factor Study Weekly Report 
 
Name       Subject #    
Date    Week no.   
 
Please circle the days you were sick this week (if any). Use the scale below to rate the 
severity of illness. If you were not sick then circle “0” on the scale at each day. 
 
0 – Feeling fine, not sick, no symptoms 
1 – Little if any interference with daily activities  
2 – Feeling sick, but can get through the day   
3 – Can do a little but must rest a lot  
4 – Confined to bed 
5 – Hospitalized 
 
Sunday 0 1 2 3 4 5 
Monday 0 1 2 3 4 5 
Tuesday 0 1 2 3 4 5 
Wednesday  0 1 2 3 4 5 
Thursday   0 1 2 3 4 5 
Friday  0 1 2 3 4 5 
Saturday  0 1 2 3 4 5 
 
Did you receive medical care?  (please circle) 
Yes    No 
If so, then what was the diagnosis? 
           






What medication, if any, did you take, or were prescribed? 
Antibiotics?  Name and dose / duration         
Antiviral? Name and dose / duration          
Antihistamine?   over the counter/prescription  
Decongestant?  over the counter/prescription  
Anti-nausea?    over the counter/prescription  
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